Get the Stockscreener App
480.25
1.06%
-5.14
After Hours:
480.25
Vertex Pharmaceuticals Inc stock is traded at $480.25, with a volume of 1.15M.
It is down -1.06% in the last 24 hours and up +7.94% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$485.39
Open:
$486.175
24h Volume:
1.15M
Relative Volume:
0.79
Market Cap:
$121.89B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
28.47
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
-9.32%
1M Performance:
+7.94%
6M Performance:
+5.63%
1Y Performance:
+2.43%
1-Day Range:
$474.71
$486.18
1-Week Range:
$474.71
$533.67
52-Week Range:
$362.50
$533.67
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance Singapore
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? - AOL.com
VRTX Maintained by UBS -- Price Target Raised to $585 - GuruFocus
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? - The Motley Fool
VRTX Maintained by Truist Securities -- Price Target Raised to $560 - GuruFocus
What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report - Barchart.com
Truist raises Vertex stock price target to $560 on Crinetics deal - Investing.com
Vertex Pharma stock holds steady as cystic fibrosis franchise underpins long-term growth outlook - ad-hoc-news.de
Drugmaker Vertex spends $10B to buy biotech firm to expand rare-disease offerings - Post and Courier
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crinetics Pharmaceuticals - GuruFocus
The week in pharma: action, reaction and insight – week to July 10, 2026 - The Pharma Letter
Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada - Yahoo Finance
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse - Yahoo Finance
Biotech Stocks Face Big $15B Hit as Vertex, Ionis Skew Flat Weekly Tape - TechStock²
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Is This Biotech Stock a Buy Near Its 52-Week High? - The Motley Fool
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal - Stock Titan
Why This Pharmaceutical Stock Jumped Close to 100% This Week - Yahoo Finance
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal - RTTNews
Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’ - Sahm
Rx Rundown: Vertex Pharmaceuticals, Real Chemistry, Vera Therapeutics and more - Medical Marketing and Media
A $10B deal, China trial scrutiny and highlights from ADA 2026 - Fierce Pharma
If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? - The Motley Fool
Vertex Pharmaceuticals Inc Stock Price Live, Charts & News - The Economic Times
IBT portfolio manager: biotech M&A boom set to continue as big pharma hunts - Proactive financial news
symbol__ Stock Quote Price and Forecast - CNN
Crinetics Pharmaceuticals (CRNX) to be Acquired by Vertex Pharma - GuruFocus
Vertex (VRTX) is One of the Best QQQ Stocks to Invest in - Yahoo Finance
Why Crinetics Stock Soared 99% This Week - Yahoo Finance
Lobbying Update: $60,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
CNBC ‘Final Trades’: Nvidia, Vertex Pharmaceuticals And More OnRoundhill Memory ETF (BATS:DRAM) - Benzinga
Vertex acquires Crinetics in $10bn endocrinology deal - European Pharmaceutical Review
Why Is Vertex Pharmaceuticals (NASDAQ:VRTX) Making Healthcare Headlines? - Kalkine Media
Vertex’s $10 Billion Crinetics Acquisition Lands Amid Record Stock High: Time to Buy? - NAI500
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.09% on Jul 8: Key Drivers Unveiled - TradingKey
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc.CRNX - Business Wire
Vertex Pharmaceutical agrees to buy Crinetics in US$10 billion deal - BNN Bloomberg
Vertex’s Crinetics Deal Balances Growth with Integration Risk - MarketBeat
PR News | Joele Frank Works Crinetics' $8.8B DealWed., Jul. 8, 2026 - O'Dwyer's PR
Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket - Sahm
Stifel cuts Crinetics stock rating to hold on Vertex acquisition - Investing.com
Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal - Yahoo Finance
American Vertex Pharmaceuticals acquires Crinetics for $10 billion - AKM.RU
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside - Trefis
Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580 - Moomoo
Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now? - Yahoo Finance
H.C. Wainwright reiterates Vertex stock Buy rating at $641 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vertex Pharmaceuticals Inc Stock (VRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
0.22%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):